The Influence of Induction Therapy for Kidney Transplantation after a Non-Renal Transplant
Authors:
- Matthew H. LevineMLMatthew H. Levine
- Peter P. ReesePRPeter P. Reese
- Roy D. BloomRBRoy D. Bloom
- Simin GoralSGSimin Goral
- Ali NajiANAli Naji
- Peter L. AbtPAPeter L. Abt
- 1 January 2012
- journal article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 7 (1) , 158-166
Abstract
Summary: Background and objectives: Non-renal transplant recipients who subsequently develop ESRD and undergo kidney transplantation are medically and immunologically complex due to comorbidities, high cumulative exposure to immunosuppressants, and sensitization to alloantigen from the prior transplant. Although prior non-renal transplant recipients are one of the fastest growing segments of the kidney wait list, minimal data exist to guide the use of antibody induction therapy (IT+) at the time of kidney after lung (KALu), heart (KAH), and liver (KALi) transplant. Design, setting, participants, & measurements: This retrospective cohort study used national registry data to examine IT use and survival after kidney transplantation. Separate multivariate Cox regression models were constructed to assess patient survival for IT+ and IT− KALu (n=232), KAH (n=588), and KALi (n=736) recipients. Results: Use of IT increased during the study period. The percentage of patients considered highly sensitized (panel reactive antibody ≥20%) was not statistically significant between IT+ and IT− groups. IT+ was not associated with improvement in 1- and 10-year patient survival for KALu (P=0.20 and P=0.22, respectively) or for KAH (P=0.90 and P=0.14, respectively). However, IT+ among KALi was associated with inferior patient survival at 1 and 10 years (P=0.04 and P=0.02, respectively). Conclusions: Use of IT for kidney transplantation among prior non-renal transplant recipients may not offer a survival advantage in KALu or KAH. However, due to limited power, these findings should be interpreted cautiously. IT+ was associated with inferior outcomes for KALi. Use of IT should be judicially reconsidered in this complex group of recipients.Keywords
This publication has 39 references indexed in Scilit:
- Wait List Death and Survival Benefit of Kidney Transplantation Among Nonrenal Transplant RecipientsAmerican Journal of Transplantation, 2010
- An Emerging PopulationClinical Journal of the American Society of Nephrology, 2010
- The Influence of Induction Therapy on Graft and Patient Survival in Patients with and without Hepatitis C after Liver TransplantationAmerican Journal of Transplantation, 2010
- Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantationClinical Transplantation, 2010
- Should heart, lung, and liver transplant recipients receive immunosuppression induction for kidney transplantation?Clinical Transplantation, 2010
- Impact of Immunosuppressive Regimen on Survival of Kidney Transplant Recipients With Hepatitis CTransplantation, 2008
- Decreased Survival in Liver Transplant Patients Requiring Chronic Dialysis: A Canadian ExperienceTransplantation, 2008
- Hepatitis C Virus Antibody Status and Survival After Renal Transplantation: Meta-Analysis of Observational StudiesAmerican Journal of Transplantation, 2005
- Chronic Renal Failure after Transplantation of a Nonrenal OrganNew England Journal of Medicine, 2003
- A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients1Transplantation, 2003